ストックスクリーナーアプリを入手
10.24
4.49%
0.44
アフターアワーズ：
10.24
前日終値:
$9.80
開ける：
$9.65
24時間の取引高:
1.32M
Relative Volume:
1.49
時価総額：
$750.92M
収益：
$54.55M
当期純損益:
$-193.57M
株価収益率:
-3.5433
EPS:
-2.89
ネットキャッシュフロー:
$-181.86M
1週間 パフォーマンス:
+16.23%
1か月 パフォーマンス:
-26.49%
6か月 パフォーマンス:
-58.58%
1年 パフォーマンス:
-27.27%
1日の値動き範囲:
$9.52
$10.27
1週間の範囲:
$8.60
$10.27
52週間の値動き範囲:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
名前
Nurix Therapeutics Inc
セクター
電話
(415) 660-5320
住所
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
10.24 | 750.92M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-17 | 開始されました | Leerink Partners | Market Perform |
| 2024-12-10 | 開始されました | BTIG Research | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-10-11 | 開始されました | Jefferies | Buy |
| 2024-09-06 | 再開されました | Robert W. Baird | Outperform |
| 2024-07-31 | 開始されました | Truist | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-09 | 開始されました | Barclays | Overweight |
| 2023-02-28 | 開始されました | Oppenheimer | Outperform |
| 2022-10-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-05-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 開始されました | Wells Fargo | Equal Weight |
| 2021-12-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-14 | 開始されました | SVB Leerink | Outperform |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-04-30 | 再開されました | Piper Sandler | Overweight |
| 2021-04-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-04-14 | 開始されました | Berenberg | Buy |
| 2020-11-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-08-18 | 開始されました | JP Morgan | Overweight |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2020-08-18 | 開始されました | Piper Sandler | Overweight |
| 2020-08-18 | 開始されました | Stifel | Buy |
すべてを表示
Nurix Therapeutics Inc (NRIX) 最新ニュース
(NRIX) Technical Data - news.stocktradersdaily.com
Nurix advances IRAK4 degrader into Phase 1 trials with FDA nod - Investing.com Canada
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential - Seeking Alpha
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher - simplywall.st
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap DownWhat's Next? - MarketBeat
Nurix Therapeutics (NRIX) Advances Experimental Drug Following FDA Clearance - GuruFocus
Nurix gets FDA nod to begin trial for its anti-inflammatory drug - Seeking Alpha
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Affinity Asset Advisors LLC - MarketBeat
FDA Clears IND for Nurix's (NRIX) IRAK4 Degrader, Phase 1 Trial Set for 2025 | NRIX Stock News - GuruFocus
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479a Novel IRAK4 Degrader for Inflammatory Conditions - The Manila Times
Nurix Therapeutics Announces FDA Clearance for GS-6791/NX-0479 IND, Phase 1 Trials Set to Begin in Q2 2025 in Collaboration with Gilead Sciences - Nasdaq
FDA Green Lights Groundbreaking IRAK4 Degrader: $420M Milestone Potential in Inflammatory Disease Fight - Stock Titan
Fmr LLC Has $200.35 Million Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Leerink Partnrs Has Optimistic Outlook of NRIX Q2 Earnings - MarketBeat
Trexquant Investment LP Reduces Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates - MSN
NRIX Stock Up as SNY In-Licenses Rights to Autoimmune Diseases Program - MSN
Vanguard Group Inc. Boosts Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wells Fargo & Company Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Price Target Lowered to $35.00 at Stifel Nicolaus - MarketBeat
Norges Bank Purchases Shares of 318,800 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
ExodusPoint Capital Management LP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Sets New 52-Week LowTime to Sell? - MarketBeat
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Polymer Capital Management HK LTD Purchases New Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Strengthens Workforce: 16 New Employees Receive Strategic Equity Awards - Stock Titan
160,500 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Springhill Fund Asset Management HK Co Ltd - MarketBeat
Q1 EPS Estimate for Nurix Therapeutics Increased by Analyst - MarketBeat
Nurix Therapeutics (NRIX) Sees Price Target Reduction Amid Ongoi - GuruFocus
UBS Adjusts Price Target on Nurix Therapeutics to $30 From $35, Keeps Buy Rating - MarketScreener
Wellington Management Group LLP Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Wells Fargo Sticks to Their Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Grains Bottom and Why - The Globe and Mail
Nurix Therapeutics price target lowered to $25 from $32 at Wells Fargo - TipRanks
Nurix Therapeutics price target lowered to $35 from $36 at Stifel - TipRanks
Nurix Therapeutics Q1 2025 Financial Highlights - TipRanks
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update | NRIX Stock News - GuruFocus
Nurix Therapeutics Inc (NRIX) Q1 2025 Earnings: EPS of ($0.67) B - GuruFocus
Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update - The Manila Times
Nurix Therapeutics Q1 Net Loss Narrows, Revenue Increases - MarketScreener
Nurix Therapeutics Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Nurix Therapeutics, Inc. SEC 10-Q Report - TradingView
Nurix Therapeutics Inc (NRIX) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):